Input 2021.01.13 23:40 | Revision 2021.01.13 23:48
Simultaneous expansion of production scale, business portfolio, and global base
Promoting new bio business through open innovation
“Accelerating the construction of factory 4, securing early orders in 2021”
Samsung Biologics President John Lim unveiled such investment plans and management strategies at the JP Morgan Healthcare Conference, the world’s largest bio-investment event held online on the 13th (Korean time).
Samsung Biologics is a strategy to expand new business with the aim of becoming a’global comprehensive bio company’ within the next 10 years. Vaccine CMO was also selected as a new business for the increased demand for vaccines after the Corona 19 epidemic. President John Lim said, “We plan to strengthen open innovation and consider investment in new pipeline and platform technologies.” “If the last 10 years focused on stabilizing the business and rapidly expanding the production scale, the next 10 years will leap into a’global comprehensive bio company’ through diversified business expansion that simultaneously expands production scale, business portfolio, and global base. “He said.
On this day, President John Lim focused on the current status of the biopharmaceutical consignment production (CMO) and consignment development (CDO) projects and future plans, which are key business areas.
Samsung Biologics plans to proceed with the construction of the 4th plant, which is the target of full-scale operation in 2023, and focus on securing early orders. The total floor area of the 4th plant is about 238,000m2 (72,000 pyeong), which is close to 240,000m2 (73,000 pyeong) of the 1st, 2nd and 3rd factories, which is about 1.5 times that of the Sangam World Cup Stadium.
.
It also announced plans for overseas expansion. Last year, the company opened a drug consignment development (CDO) research and development (R&D) center in San Francisco, a representative bio-cluster in the United States. In the future, it is also planning to enter Boston, Europe, and China. It is also planning to expand the business stage at home and abroad by reviewing securing CMO overseas production plants. Along with this, the construction of the 2nd Bio Campus of 100,000 pyeong in Songdo, Incheon is underway.
In the long term, the company presented a vision of establishing the world’s No. 1 position in the CMO, CDO, and biosimilar fields, and reviewing the new drug business based on accumulated innovative technology and experience, so that the three business divisions will become the new growth engines of the Samsung bio industry.
Last year, Samsung Biologics achieved its targets in all business areas. In the case of CMO, it achieved the largest order performance ever, with an annual cumulative of 1.85 trillion won. It is also a representative example of starting to produce an antibody treatment for Corona 19. Samsung Biologics signed a long-term contract to produce COVID-19 antibody treatment with Eli Lilly in the US in May of last year. In April of last year, it signed a contract to produce COVID-19 antibody treatment with Glaxos Miscline (GSK) in the UK. It is explained that the company has achieved orders close to its maximum production capacity (CAPA) from the first and second plants to the third plant.
In the recent bio industry, demand for CMOs and CDOs is on the rise due to global outsourcing trends, expanding pipelines, and increasing new bio companies. President John Lim emphasized, “We will respond to market demand and various customer needs and focus on early orders for the 4th plant to secure the maximum amount of orders before operation.”
Biosimilars plan to accelerate their targeting in major global markets such as the United States while maintaining market dominance in the European market. It also plans to expand the pipeline for new disease biosimilars.
The JP Morgan Healthcare Conference is an annual event held by the US investment bank JP Morgan, and is a global bio investment conference where more than 9000 investors and 450 bio companies around the world participate to discuss investment. About 30 domestic pharmaceutical and bio companies attended. This year, Corona 19 is being held online for four days from the 11th to the 14th (local time).
